Researchers @HkuPharm have developed an innovative AI-based cardiovascular risk prediction tool that can predict heart disease up to 15 years before clinical onset.
https://t.co/mihC5wpUpf
An oral formulation of arsenic trioxide (oral-ATO) to treat acute promyelocytic leukaemia, a blood cancer, invented by researchers at HKUMed has become the first anti-cancer drug created in Hong Kong to obtain FDA and EMA designations.
For more: https://t.co/nbiBGhs1dv
Thanks for sharing it 🙏 I was excited to read the RCT, important study
You can access the editorial here 👇
https://t.co/KMBW8rZCk3
@HyperAHA
First author @ctavaresleticia@MonashBiol
https://t.co/MWd1pkU3DC
Unexpected evidence for inconsistencies in the BP-lowering effects of short-chain fatty acids. Thank you @FZMarques for your editorial highlighting the considerations while investigating GM-based therapeutics @HyperAHA
We've recently published a paper in the JCI that identifies post-translationally modified peptides that are antigens in hypertension. Thanks to all my colleagues for their hard work on this project:
New #bloodpressure measurement devices such as cuff-less wrist monitors are likely to play an important role in future – but several challenges remain before these new technologies can be introduced widely - new @ISHBP position paper out today.
Read more: https://t.co/VGmnZoJvo4
New study reveals 7 novel metabolites influencing BP regulation via GPCRs, incretins, selenium, & mitochondrial pathways, highlighting effective protein dietary strategies for hypertension management. @TulaneSPHTM@Changwei001
https://t.co/FrtQXqEeqV
It’s a wrap. Learned a lot at #Hypertension24 and had a great time presenting our research on sex specific associations between gut microbiota and 24-hour BP variability. Thankful for the useful feedback and discussions! @AHAMeetings @hkustroke @GQworks